

Going beyond Commitment,



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th JUNE 2012

PART - I		Rs. in Lacs			
Sl. No.	PARTICULARS	Quarter Ended			Previous Year Ended
		30/6/2012	31/03/2012	30/06/2011	31/3/2012
		Unaudited	Un-audited	Unaudited	Audited
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	7,052.72	6,289.42	4,463.29	20,420.78
	(b) Other operating income	-	-	-	-
	Total income from operations (net)	7,052.72	6,289.42	4,463.29	20,420.78
2	Expenses				
	a) Cost of materials consumed	2,144.63	2,487.22	1,854.11	8,145.56
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	330.84	418.09	(10.62)	(564.74)
	d) Employee benefits expense	651.73	633.69	495.16	2,283.03
	e) Depreciation and amortisation expense	183.23	182.78	138.73	599.79
	f) Other expenses - Manufacturing Exps	848.55	791.31	554.07	2,667.83
	- Selling Exps	100.21	43.86	48.41	216.91
	- Administrative Exps	517.42	607.50	257.24	1,704.57
	- R & D Exps	874.68	821.77	747.82	3,304.91
	- Provision for MTM on Forward Contracts	250.96	(854.63)	-	348.06
	Total expenses	5,902.25	5,131.59	4,084.92	18,705.92
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,150.47	1,157.83	378.37	1,714.86
4	Other Income	52.47	12.52	20.28	190.25
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	1,202.94	1,170.35	398.65	1,905.11
6	Finance costs	321.92	420.86	163.58	990.93
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	881.02	749.49	235.07	914.18
8	Exceptional Items	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	881.02	749.49	235.07	914.18
10	Tax Expenses	84.68	34.91	(101.02)	(522.06)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	796.34	714.58	336.09	1,436.24
12	Extraordinary Items (net of tax expense ` ____ Lakhs)	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	796.34	714.58	336.09	1,436.24
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority interest *	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *				
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				11,584.83
19.i	Earning Per Share (EPS) (before extraordinary items) (of ` Rs.1/- each) (not annualised):				
	a) Basic	0.68	0.61	0.29	1.23
	b) Diluted	0.68	0.61	0.29	1.23
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	0.68	0.61	0.29	1.23
	b) Diluted	0.68	0.61	0.29	1.23

PART - II					
		30/6/2012	31/03/2012	30/06/2011	31/3/2012
A	PARTICULARS OF SHAREHOLDING	Unaudited	Un-audited	Unaudited	Audited
1	Public share holdings - Number of shares - Percentage of Share holding	42,679,160 36.56%	42,679,160 35.56%	42,858,960 36.72%	42,679,160 36.56%
2	Promoters and promoter group Shareholding**				
	a) Pledged / Encumbered	NIL	NIL	NIL	NIL
	- Number of shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
	b) Non-Encumbered	74,052,828	74,052,828	73,873,028	74,052,828
	- Number of shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	63.44%	63.44%	63.28%	63.44%
Particulars		3 months ended (30/06/2012)			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	0			
	Received during the quarter	20			
	Disposed of during the quarter	20			
	Remaining unresolved at the end of the quarter	0			

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED					Rs.in Lacs
PARTICULARS	Quarter Ended			Year Ended	
	30/6/2012	31/03/2012	30/06/2011	31/3/2012	
	Unaudited	Unaudited	Unaudited	Audited	
1	SEGMENT REVENUE :-				
	a) Manufacturing (CRAMS)	6,514.95	5,921.54	4,305.07	19,168.87
	b) Services (DDDSS)	537.77	367.88	158.22	1,251.91
	c) Research & Development	-	-	-	-
	Net Sales from Operations	7,052.72	6,289.42	4,463.29	20,420.78
2	SEGMENT RESULTS :-				
	Profit/(Loss) before tax and interest:				
	a) Manufacturing (CRAMS)	2,494.37	1,646.42	1,327.31	6,507.91
	b) Services (DDDSS)	231.20	134.84	68.55	531.83
	c) Research & Development	(874.68)	(821.77)	(747.82)	(3,304.91)
	TOTAL	1,850.89	959.49	648.04	3,734.83
Less:	i) Interest	298.14	318.43	163.58	888.50
	ii) Other Un-allocable exps net off un-allocable Income	671.73	(108.43)	249.39	1,932.15
	Total Profit Before Tax	881.02	749.49	235.07	914.18
3	CAPITAL EMPLOYED				
	(Segment Assets - Segment Liabilities)				
	a) Manufacturing (CRAMS)	11,483.10	10,704.10	11,276.13	10,704.10
	b) Services (DDDSS)	3,131.68	3,298.34	712.73	3,298.34
	c) Research & Development	2,525.28	2,228.26	3,513.00	2,228.26
	d) Net assets which are not segmented and used commonly	1,564.05	2,023.90	3,494.93	2,023.90
	TOTAL	18,704.11	18,254.60	18,996.79	18,254.60

- Notes: 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 14th Aug'12
2) Previous years figures have been regrouped / reclassified whenever necessary.
3) The limited review has been completed by the Statutory Auditors.
4) Provision for MTM Losses pertain to Forward Contracts entered for covering the future receivables in USD.
5) Suven Nishtaa pharma pvt Ltd, the 100% subsidiary, has been merged wef 1 st Jan 2012 and accordingly the results have been prepared. Hence the current year's figures are not comparable with the previous year figures.
6) The figures of the last quarter of the previous year are the balancing figures between the audited figures for the full financial year and the published 'year to date figures' upto the third quarter.
7) The Board has recommended a Dividend of Re.0.30 per Equity share(i.e.30% of face value of Rs.1/- each) for the year 2011-12 , subject to approval of the shareholders in the ensuing Annual General Meeting.
8) The variation in net profits between audited results as on 31/03/2012 to the unaudited results declared on 4/5/2012 is on account of merger of Suven Nistaa pharma pvt Ltd (100% subsidiary) w e f 1 st Jan '2012.

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad
Date : 14th Aug'2012

VENKAT JASTI
Chairman & CEO

We Deliver